Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This clinical study is being conducted at multiple sites to determine the activity, safety
and tolerability of XL784 when given daily to patients with albuminuria due to diabetic
nephropathy. XL784 is a small molecule reno-protective metalloproteinase inhibitor,
inhibiting both ADAMs (including ADAM10, a target of significant interest because of its
important role in blood vessel formation and cell proliferation, and ADAM17/TACE, activation
of which has been associated with renal deterioration) and MMPs (including MMP-2 and MMP-9).
XL784 was specifically optimized to be MMP-1 sparing, which may be clinically significant
because inhibition of MMP-1 has been hypothesized to be associated with musculoskeletal
toxicity.